salmonella typhimurium A1-R

Salmonella typhimurium A1-R is a genetically modified, tumor-targeting strain of *Salmonella enterica* serovar Typhimurium. Engineered to be auxotrophic for leucine and arginine, it preferentially proliferates in tumor microenvironments, where these amino acids are available, while sparing normal tissues[1][4][6]. The bacterium directly kills cancer cells by infecting, replicating within, and lysing tumor cells; it also induces central tumor necrosis via growth in hypoxic/anaerobic conditions[1][4]. In preclinical models, A1-R has demonstrated efficacy against a wide range of recalcitrant cancers, including melanoma, glioma, breast, pancreatic, colon, prostate, ovarian, cervical, lung cancer, osteosarcoma, and fibrosarcoma[1][2][4][6]. It has also been shown to synergize with chemotherapeutic and molecular-targeted agents. Mechanistically, it triggers both innate and adaptive antitumor immune responses through activation of cytokines (e.g., interferon-γ) and recruitment of immune cells via Toll-like receptor 4 signaling[1]. The strain was primarily developed and characterized by AntiCancer and academic collaborators[4][5].